Selank (TP-7)
Synthetic heptapeptide analogue of the naturally occurring immunomodulatory peptide Tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro tripeptide. Developed in Russia as an anxiolytic and nootropic agent; acts via allosteric modulation of GABA-A receptors and neurotrophin upregulation without sedative or addictive properties. Not approved by US FDA, EMA, or EDA; FDA Category 2 compounding substance.
60-Second Scientific Briefing
Selank is a synthetic heptapeptide derived from the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro tripeptide. Developed in Russia as an anxiolytic and nootropic agent for generalized anxiety disorder. It is NOT FDA-approved.
What is Selank?
Pharmacological Classification & Molecular IdentitySynthetic heptapeptide composed of the natural tetrapeptide tuftsin linked to the metabolically stabilizing tripeptide Pro-Gly-Pro.
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Modulates GABA-ergic neurotransmission, allosterically interacts with GABA-A receptors, and influences serotonin and dopamine metabolism in the brain.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNot approved by the US FDA or EMA for any medical condition. Holds regional regulatory registration in Russia.
Selank is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesRegional clinical studies evaluated intranasal Selank in patients with generalized anxiety disorder (GAD) and neurasthenia compared to benzodiazepines.
Clinical Evidence
Regional clinical studies evaluated intranasal Selank in patients with generalized anxiety disorder (GAD) and neurasthenia compared to benzodiazepines.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesGenerally reported as non-sedating without withdrawal symptoms in Russian literature. Local nasal dryness or irritation can occur.
Lack of large-scale international multi-center randomized controlled trial safety data.
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNOT ESTABLISHED in FDA jurisdictions. Russian pharmaceutical labeling prescribes 0.15% intranasal drops.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Synthetic heptapeptide composed of the natural tetrapeptide tuftsin linked to the metabolically stabilizing tripeptide Pro-Gly-Pro.
- Targets & Selectivity: Modulates GABA-ergic neurotransmission, allosterically interacts with GABA-A receptors, and influences serotonin and dopamine metabolism in the brain.
- Regional clinical studies evaluated intranasal Selank in patients with generalized anxiety disorder (GAD) and neurasthenia compared to benzodiazepines.
- Safety considerations: Generally reported as non-sedating without withdrawal symptoms in Russian literature. Local nasal dryness or irritation can occur.
? Unknown / Under Ongoing Investigation
- Lack of large-scale international multi-center randomized controlled trial safety data.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysSelank is classified as a Tuftsin-Derived Anxiolytic Neuropeptide. Molecular structure: Synthetic heptapeptide composed of the natural tetrapeptide tuftsin linked to the metabolically stabilizing tripeptide Pro-Gly-Pro..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Selank exerts biological activity via Modulates GABA-ergic neurotransmission, allosterically interacts with GABA-A receptors, and influences serotonin and dopamine metabolism in the brain..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Regulatory status: Not approved by the US FDA or EMA for any medical condition. Holds regional regulatory registration in Russia.
Investigational and research-only compounds cannot be legally distributed or marketed as prescription drugs.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Clinical evaluation status: Regional clinical studies evaluated intranasal Selank in patients with generalized anxiety disorder (GAD) and neurasthenia compared to benzodiazepines.
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Reported safety profile: Generally reported as non-sedating without withdrawal symptoms in Russian literature. Local nasal dryness or irritation can occur.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Key scientific uncertainties: Lack of large-scale international multi-center randomized controlled trial safety data.
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
NOT ESTABLISHED in FDA jurisdictions. Russian pharmaceutical labeling prescribes 0.15% intranasal drops.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Storage status: NOT ESTABLISHED for Western retail distribution. Stored under refrigeration at 2°C to 8°C.
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Yes. Unapproved pharmacological substances are strictly prohibited at all times in competitive sports under WADA Category S0 (Non-approved substances) or Category S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2008-01-01)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesEfficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia ↗
https://pubmed.ncbi.nlm.nih.gov/18454096/